ArticleJournal of virology2005
Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- In vitro inhibition of HIV-1 replication in autologous CD4Virologica Sinica · 2017Article
- Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis.PLoS pathogens · 2017Article
- Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.Statistical communications in infectious diseases · 2017Article
- Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions.Journal of immunology research · 2015Article
- Functions of Antibodies.Microbiology spectrum · 2014Article
- Review
- Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Frontiers in immunology · 2014Review
- Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.Current HIV research · 2013Article
- Scaffold functions of 14-3-3 adaptors in B cell immunoglobulin class switch DNA recombination.PloS one · 2013Article
- The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization.PloS one · 2012Article
- New paradigms for HIV/AIDS vaccine development.Annual review of medicine · 2012Review
- Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.Retrovirology · 2011Article
- B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.Trends in molecular medicine · 2011Article
- Review
- The humoral response to HIV-1: new insights, renewed focus.The Journal of infectious diseases · 2010Review
- Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.Nature medicine · 2010Article
- Is developing an HIV-1 vaccine possible?Current opinion in HIV and AIDS · 2010Review
- Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.The Journal of experimental medicine · 2010Article
- Role of humoral immunity in host defense against HIV.Current HIV/AIDS reports · 2010Review
- Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies.Viruses · 2009Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Antibodies can prevent lentivirus infections in animals and may play a role in controlling viral burden in established infection. In preventing and particularly in controlling infection, antibodies likely function in the presence of large quantities of virus. In this study, we explored the mechanisms by which antibodies neutralize large inocula of human immunodeficiency virus type 1 (HIV-1) on different target cells. Immunoglobulin G (IgG) from HIV-infected patients was tested for neutralizing activity against primary R5 strains of HIV-1 at inocula ranging from 100 to 20,000 50% tissue culture infective doses. At all virus inocula, inhibition by antibody was enhanced when target cells for virus growth were monocyte-depleted, peripheral blood mononuclear cells (PBMCs) rather than CD4(+) lymphocytes. However, enhanced inhibition on PBMCs was greatest with larger amounts of virus. Depleting PBMCs of natural killer (NK) cells, which express Fc receptors for IgG (FcgammaRs), abrogated the enhanced antibody inhibition, whereas adding NK cells to CD4(+) lymphocytes restored inhibition. There was no enhanced inhibition on PBMCs when F(ab')(2) was used. Further experiments demonstrated that the release of beta-chemokines, most likely through FcgammaR triggering of NK cells, contributed modestly to the antiviral activity of antibody on PBMCs and that antibody-coated virus adsorbed to uninfected cells provided a target for NK cell-mediated inhibition of HIV-1. These results indicate that Fc-FcgammaR interactions enhance the ability of antibody to neutralize HIV-1. Since FcgammaR-bearing cells are always present in vivo, FcgammaR-mediated antibody function may play a role in the ability of antibody to control lentivirus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.